ENTPD2 antibodies, combination therapies, and methods of using these antibodies and combination therapies

CN119192383APending Publication Date: 2024-12-27NOVARTIS AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411340316.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-05-30
Filing Date
2019-05-29
Publication Date
2024-12-27

Smart Images

  • Figure BDA0005059492810000301
    Figure BDA0005059492810000301
  • Figure BDA0005059492810000311
    Figure BDA0005059492810000311
  • Figure BDA0005059492810000321
    Figure BDA0005059492810000321
Patent Text Reader

Abstract

Provided herein are antibodies, or antigen-binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), such as monoclonal antibodies, or antigen-binding fragments thereof, and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen-binding fragment thereof and at least one additional therapeutic agent, as well as methods of using these combination therapies.
Need to check novelty before this filing date? Find Prior Art